Synapse - Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2 Meeting Abstract

Authors:	Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; Drullinsky, P.; Friedberg, J. W.; Grieve, C.; Hamilton, A.; Hamlin, P. A.; Hoppe, R.; Horwitz, S. M.; Khan, N.; Matasar, M. J.; Noy, A.; Palomba, M. L.; Schoder, H.; Straus, D. J.; Vemuri, S.; Yahalom, J.; Yang, J. C.; Younes, A.; Zelenetz, A. D.; Moskowitz, C. H.; Kumar, A.; Moskowitz, A. J.
Abstract Title:	Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
Meeting Title:	64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	140
Issue:	Suppl. 1
Meeting Dates:	2022 Dec 10-13
Meeting Location:	New Orleans, LA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-11-15
Start Page:	1756
End Page:	1758
Language:	English
ACCESSION:	WOS:000893223201316
DOI:	10.1182/blood-2022-156382
PROVIDER:	wos
Notes:	Meeting Abstract -- Source: Wos